Cullinan Therapeutics Inc.
Last updated September 27, 2026
Organization details
- Legal name
- Cullinan Therapeutics Inc.
- Former names
- Cullinan Oncology, Inc. Cullinan Management, Inc.
- Ownership
- Public
- Status
- Active
- SIC code
- 2836 — Biological Products, (No Diagnostic Substances)
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- Cambridge
- Headquarters state / province
- Massachusetts
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- CGEM
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001789972
- EIN
- 81-3879991
Board of directors
-
Andrew R. Allen · DirectorSince 2025
-
Anne-Marie Martin · DirectorSince 2023
-
Anthony Rosenberg · DirectorSince 2023
-
David D. Meek · DirectorSince 2024
-
David P. Ryan · DirectorSince 2024
- Since 2024
-
Mittie Doyle · DirectorSince 2025
-
Nadim Ahmed · Director · President and CEOSince 2023
-
Stephen W. Webster · DirectorSince 2023
-
Thomas Ebeling · DirectorSince 2023
Chief executives
Nadim Ahmed
· President and CEO
Dates unknown
Director election results
Annual meeting of June 16, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
74.5%
-
75.6%
Board connections
4 of this board's directors also sit on 8 other boards.
- via Mary Thistle
- via Mary Thistle
- via Nadim Ahmed
- via Stephen W. Webster
- via Mary Thistle
- via Stephen W. Webster
- via Mary Thistle
- via David D. Meek
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $13,325,286
- 8 purchases by 2 insiders
- Sold, last 12 months
- $2,509,396
- 28 sales by 5 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Sep 8, 2026 | Michaelson Jennifer Officer (Chief Scientific Officer) | Option exercise | +4,000 | $4.30 | $17,200 |
| Sep 8, 2026 | Michaelson Jennifer Officer (Chief Scientific Officer) | Open-market sale | −8,000 | $21.57 | $172,560 |
| Aug 13, 2026 | Michaelson Jennifer Officer (Chief Scientific Officer) | Option exercise | +30,000 | $4.30 | $129,000 |
| Aug 13, 2026 | Michaelson Jennifer Officer (Chief Scientific Officer) | Open-market sale | −30,000 | $20.26 | $607,800 |
| Jul 6, 2026 | Michaelson Jennifer Officer (Chief Scientific Officer) | Option exercise | +4,000 | $4.30 | $17,200 |
| Jul 6, 2026 | Michaelson Jennifer Officer (Chief Scientific Officer) | Open-market sale | −8,000 | $17.82 | $142,560 |
| Jun 30, 2026 | Fenton Mary Kay Officer (Chief Financial Officer) | Grant or award | +1,541 | $8.60 | $13,253 |
| Jun 30, 2026 | SUMER JACQUELYN L Officer (Chief Legal Officer) | Grant or award | +2,470 | $8.60 | $21,242 |
| May 5, 2026 | Michaelson Jennifer Officer (Chief Scientific Officer) | Option exercise | +4,000 | $4.30 | $17,200 |
| May 5, 2026 | Michaelson Jennifer Officer (Chief Scientific Officer) | Open-market sale | −7,800 | $14.60 | $113,880 |
| May 5, 2026 | Michaelson Jennifer Officer (Chief Scientific Officer) | Open-market sale | −200 | $15.58 | $3,116 |
| Mar 5, 2026 | Michaelson Jennifer Officer (Chief Scientific Officer) | Option exercise | +4,000 | $4.30 | $17,200 |
| Mar 5, 2026 | Michaelson Jennifer Officer (Chief Scientific Officer) | Open-market sale | −8,000 | $15.68 | $125,440 |
| Feb 25, 2026 | Michaelson Jennifer Officer (Chief Scientific Officer) | Open-market sale | −1,780 | $14.14 | $25,169 |
| Feb 24, 2026 | Nadim Ahmed Director, Officer (President and CEO) | Open-market sale | −13,515 | $14.47 | $195,562 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.